Fig. 5.

Development of facial muscle weakness over time in Patient 1 (a, b) and Patient 2 (c, d) with infantile-onset Pompe disease treated with ERT. Comparison at 4 months of age (a, c) with their most recent photographs (b, d). Facial muscle weakness, present in Patient 1 at both ages, is absent at both ages in Patient 2. Patient 1 and Patient 2 initiated ERT at 4 months and 12 days of age, respectively.